BlueRun Ventures Early-Stage Portfolio Company Shian Biosciences Enters Exclusive ALK7 siRNA Licensing Agreement with GSK | BlueRun Ventures Family Headlines

On May 6, 2026, SiranBio announced a global exclusive licensing agreement with GSK for SA030 (excluding mainland China, Hong Kong, Macau, and Taiwan). GSK will pay an upfront fee and milestone payments totaling up to $1.005 billion, plus tiered royalties.

SA030 is a potentially first-in-class, long-acting siRNA drug targeting ALK7 for the treatment of metabolic and cardiovascular diseases, and has recently entered Phase I clinical trials.

BlueRun Ventures led both of SiranBio's funding rounds in 2024 and 2025, establishing a close connection with the company early in its founding and continuously witnessing the team's progress in platform development and pipeline advancement.

SiranBio has established an internationally competitive nucleic acid drug technology platform system with independent intellectual property rights, encompassing the eSAFE chemical modification technology, the Stork-W dual-target siRNA platform, and both intrahepatic and extrahepatic delivery platforms. Based on these platforms, the company has advanced SA1211, the world's first single-molecule dual-target siRNA candidate drug, into clinical development; meanwhile, SA030, an ALK7 siRNA candidate drug developed based on the STORK-F adipose tissue delivery platform, has also become one of the first ALK7 siRNA candidate drugs globally to enter clinical development.

BlueRun Ventures has always focused on differentiated cutting-edge biotech technology platforms. Congratulations to Siran on having its platform capabilities and pipeline value recognized by an MNC partner! We look forward to Siran's dual-target and extrahepatic delivery platforms continuing to produce differentiated pipelines and achieving outstanding results in the clinical stage!

In the field of metabolic and cardiovascular disease treatment, an increasing body of research is turning its attention to a deeper question: the risks patients face do not stem from a single metabolic indicator alone, but are often intertwined with visceral adipose tissue (VAT), chronic inflammation, and long-term cardiometabolic abnormalities. Cardiometabolic disease is the leading cause of death in approximately 50% of patients with chronic kidney and liver diseases, which means that finding new intervention pathways around residual cardiometabolic risk carries real and clear clinical significance.

It is against this backdrop that ALK7 has emerged as a therapeutic mechanism of interest. Available data suggests that targeting ALK7 may reduce abdominal fat — particularly visceral adipose tissue — while preserving lean body mass, and further improve insulin sensitivity, lipid profiles, and adipocyte-driven inflammation. For diseases at the intersection of metabolism and cardiovascular health, the significance of this mechanism lies in its attempt to address risk management at a more fundamental pathological level, rather than merely improving individual symptoms.

SA030 is a long-acting siRNA drug targeting ALK7 that has recently entered Phase I clinical trials. One of its distinguishing features is its differentiated long-acting properties, enabling intervention in the underlying inflammation associated with cardiometabolic risk through adipocyte-targeted delivery and a low-frequency dosing regimen.

From a positioning perspective, SA030 is not designed around a single weight management goal, but rather aims to establish a more complete chain of action between fat reduction, inflammation control, and cardiometabolic risk improvement. For clinicians, the value of such a mechanism lies more in whether it can fill the long-undercovered risk management gaps outside the existing therapeutic framework.

Another noteworthy aspect of SA030 is that its relationship with existing established therapies is not one of simple replacement. SA030 offers a complementary and distinct mechanism to GLP-1 agonists and SGLT2 inhibitors, providing support for potential future combination regimens to reduce residual cardiometabolic risk that current therapies have not fully addressed.

This means that SA030's value lies not merely in "creating another new-mechanism project," but in its potential to assume a clearer functional position within future treatment combinations. For complex chronic diseases like metabolic and cardiovascular conditions, the ability to complement existing regimens is often an important prerequisite for new therapies to truly enter clinical practice.

Viewing this deal within the company's broader development trajectory, SA030 is not an isolated project, but rather a natural outcome of SiranBio's accumulated platform capabilities. The company has already established an independent intellectual property system around single-target and dual-target nucleic acid drug technology platforms and extrahepatic delivery platforms, including eSAFE chemical modification technology, the STORK intrahepatic and extrahepatic delivery technology platform, and the dual-target nucleic acid technology platform.

These platform capabilities mean the company is not merely advancing individual projects, but building a small nucleic acid drug R&D system at a more fundamental level. SiranBio has currently laid out first-in-class and best-in-class small nucleic acid drug pipelines for both intrahepatic and extrahepatic applications, covering antiviral, cardiovascular and metabolic diseases, autoimmune conditions, and central nervous system disorders, among other directions. This platform-style positioning also makes SiranBio appear to outsiders not just as a company advancing a single asset, but as an innovative drug R&D platform with the potential to continuously produce new programs.

Moonshot AI K2.6 Released and Open-Sourced: Comprehensive Advances in Coding, Long-Horizon Tasks, and Agent Swarm Capabilities | BlueRun Ventures Family Headlines

$2 Billion Sudo Tech's Embodied Debut Is a Big Move! Zero Real-Robot Data, Zero-Shot, Achieves 98% First-Attempt Grasp Success Rate | BlueRun Ventures Family Headlines

If You're in the Fight, You Should Be in the Room: Booming Club First Round Recruitment